Skip to content

Effect of liposomal bupivacaine paravertebral block on postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery: a randomized controlled trial

Application of liposomal bupivacaine paravertebral block on postoperative analgesia after video-assisted thoracoscopic surger

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095090
Enrollment
Unknown
Registered
2025-01-01
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

BD group:Bupivacaine 75mg+ dexamethasone 4mg+0.9% NaCl, total 20 ml
LB group:Bupivacaine 37.5 mg+ liposomal bupivacaine 133 mg+0.9% NaCl, total 20 ml

Sponsors

Xishan People's Hospital of Wuxi City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged =18 years 2.Body mass index was 18.5 ~ 30 kg/m^2 3.The American Society of Anesthesiologists(ASA) classification is I ~ ? level 4.Patients undergoing thoracoscopic lung resection surgery

Exclusion criteria

Exclusion criteria: 1.Severe heart and lung disease 2.Chronic pain treatment or chronic steroid therapy 3.Mental illness 4.Allergy to the study drugs

Design outcomes

Primary

MeasureTime frame
The duration of analgesia;Postoperative adverse effects;

Secondary

MeasureTime frame
Oxycodone consumption at various postoperative periods;NRS scores at rest and cough at different time points during the 72-hour postoperative period;Area under the curve of pain scores at rest and cough during 0-72 hours postoperatively(AUC NRS 0-72);Patient satisfaction;

Countries

China

Contacts

Public ContactJing Li

1128 Dacheng Road,Xishan District,Wuxi,Jiangsu,China

pieland@163.com+86 150 6189 9191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 25, 2026